Mass General Cancer Center’s Post

A new blood test for colon cancer screening has just won FDA approval. This innovative test offers a less invasive option for early detection and could be a game-changer in cancer care. Learn more about this promising development and how it might benefit you in the full story below. https://lnkd.in/eTGZ-srH #ColonCancer #HealthInnovation #FDAApproval #retirees

Have you ever heard of #Tamoxifen? 🎗️ This drug plays a crucial role in the treatment of certain types of breast cancer and is also prescribed to women at high risk of developing the disease. As a non-steroidal antiestrogen, tamoxifen works by blocking the effects of estrogen, a hormone that some cancer cells rely on to grow. By preventing estrogen from binding to these cells, it reduces the risk of cancer spreading and helps stop it from recurring. Days such as #InternationalBreastCancerAwarenessMonth remind us of the key role of treatments such as tamoxifen in both the cure and prevention of this cancer. Because for us the goal always remains the same: to achieve a future in which this disease is increasingly curable and less widespread 🎀 #BreastCancerAwareness #Flarer #Pharmaceuticals 

Romidepsin may be active in specific subtypes of peripheral t-cell lymphomas, which is why it remains in the NCCN guidelines despite no FDA approval.  An analysis of the failed romidepsin plus CHOP (Ro-CHOP) trial found that it may have a benefit in the T-follicular helper (TFH) cell phenotype.  Because the trial failed, the indication for romidepsin has already been withdrawn and it is no longer indicated for peripheral t-cell lymphomas, meaning it would be difficult to give this therapy to TFH patients.  This commentary in the JCO provides some lessons learned from the clinical trial.  First, we may want to be more conservative when calculating power, as standard-of-care arms may be more effective than we expect.  Second, we need to be better at understanding cancer heterogeneity and incorporating that in the trial design.  Third, it's difficult to recruit for rare diseases, so you may only have one chance at a clinical trial.  I can understand why the trial was not designed to look at the T-follicular helper (TFH) cell phenotype, since it would have made the recruitment process even more difficult, but in retrospect it was the wrong decision. #istodax #PTCL https://lnkd.in/egXr5zmh

How do you choose the right liquid biopsy test for patients with cancer? Here are some considerations: Is the liquid biopsy approved by the U.S. Food and Drug Administration (FDA)? Is it validated by oncologists globally and supported by reliable evidence? Is the test result accurate? Is the test result delivered quickly? Does it test for relevant markers in cancer treatment? As a patient with cancer, you deserve to know a detailed profile of the tumour. With liquid biopsies, this information is now possible within one week upon sample receipt in the laboratory which means you can start suitable treatment sooner. Speak to your doctor today about comprehensive liquid biopsies that can help guide treatment decisions for you. Visit us at https://lnkd.in/dVEkKyRC to find out more about Guardant Health’s comprehensive genomic profiling tests. #guardanthealthamea #guardanthealth #comprehensivegenomicprofiling #precisiononcology #liquidbiopsy #liquidissolid #cancerpatients

With World Cancer Day upon us, I’m reminded of the first time I was confronted, decades ago, through a dear relative, with cancer - back then largely an uncurable disease. Fast forward: Today I know of a dozen family members (some very close) and friends (also some very close), who have survived, in some cases not only one but multiple cancers. Isn’t that amazing progress? And only in one important area … think about the wider medical and pharmaceutical progress achieved in the past few years! Latest approvals, including for FDA fast track reviews, only show the ongoing game change in cancer treatment, through antibody-drug conjugates – more targeted, in many cases fewer side effects, and generally gentler on the body. At Deallus, we’re incredibly excited to partner with several players deeply engaged on this innovative frontier, in Medical, Clinical, Market Access, and Commercial dimensions, and all for the benefit of patients, current and future. #cancer #worldcancerday #pharmaindustry #Deallus #competitiveintelligence

Congratulations on the successful approval of our Diagnostics Kit for Methylated Genes of Gastric Cancer by National Medical Products Administration (NMPA). We're proud to introduce our groundbreaking blood-based test for early diagnosis of gastric cancer, which detects the methylation status of Reprimo/TCF4/SDC2 genes. We have conducted robust clinical trials with 1490 clinical samples, which included 468 gastric cancer cases and 1022 non-gastric cancer cases. The results were impressive: our test showed a sensitivity of 80.77%, a specificity of 92.07%, and a consistency rate of 88.52%. It requires only 5mL of peripheral blood. With advantages such as painlessness, non-invasiveness, safety, simplicity, and high accuracy, it shows promising prospects in gastric cancer screening. This remarkable product is set to revolutionize the early detection of gastric cancer, providing hope and early treatment options for patients around the globe. Don't wait - early detection can save lives! #GastricCancer #EarlyDiagnosis #BloodTest #CancerDetection #NMPAapproved #IVD Contact us 📧>>marketing@lepu-medical.com Visit #lepumedical website for more >>en.lepumedical.com

On June 26, 2024, we recognise Rare Cancers Awareness Day. Though less common individually, rare cancers collectively account for about 25–30% of all cancer diagnoses and 25% of cancer deaths globally, representing a substantial burden of disease. At Prospection, we are proud to be contributing to the fight against such cancers by helping pharma clients gain valuable insights on the patient care journey using patient-centric intelligence (PCI). 🟢 Learn more about Prospection's work with a large pharma client that helped improve understanding of treatment patterns and outcomes for patients with the rare blood cancer chronic lymphocytic leukaemia (CLL) 👉 https://lnkd.in/ge9CruMK Rare Cancers Australia

🎗️ Breast Cancer Awareness Day At Curity Pharma, we stand in solidarity with all those affected by breast cancer, recognizing the challenges faced by patients and their families. On this Breast Cancer Awareness Day, we reaffirm our commitment to advancing healthcare solutions that can make a difference in the lives of those battling this disease. Pharmaceutical cannabis has shown promise in helping patients manage symptoms associated with cancer treatment, including pain, nausea, and anxiety. We believe in the power of science and innovation to bring comfort and hope to breast cancer patients. Let’s continue to raise awareness, support research, and work towards a future where every patient has access to the best possible care. Together, we can make a difference 🙌🤗 #CurityPharma #MedicalCannabis #HealthcareInnovation #BreastCancerAwareness #PatientSupport #CannabisForHealth #CannabisScience